LK
DNLI icon

Lumbard & Kellner’s Denali Therapeutics DNLI Stock Holding History

Lumbard & Kellner’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
98,282
+3,500
+4% +$71.9K 0.77% 43
2026
Q1 		$1.82M Buy
+94,782
New +$1.89M 0.63% 44

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lumbard & Kellner's DNLI Position: Q2 2026 in Review

Lumbard & Kellner increased its Denali Therapeutics (DNLI) stake by 3.7% in Q2 2026, buying an estimated $71.9K and bringing the position to 98,282 shares worth $2.53M. The position accounts for 0.77% of the portfolio, ranked #43.

Lumbard & Kellner first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Lumbard & Kellner held 98,282 shares of Denali Therapeutics worth $2.53M as of Q2 2026.
  • Lumbard & Kellner bought 3,500 Denali Therapeutics shares in Q2 2026, an estimated $71.9K.
  • Denali Therapeutics made up 0.77% of Lumbard & Kellner's portfolio in Q2 2026, its #43 holding.
  • Lumbard & Kellner first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Lumbard & Kellner's 13F filing for Q2 2026, filed 6 Aug 2026.